BELOGAL
LIVE

Serial Number

79192560

Owner

Double Bond Pharmaceuticals AB

Attorney

Mark Harrison

Filing Date

Mar 2, 2016

Add to watchlist:

No watchlists yet
View on USPTO

BELOGAL Trademark

Serial Number: 79192560 • Registration: 5158538

BELOGAL is a trademark filed by Double Bond Pharmaceuticals AB on March 2, 2016. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

Double Bond Pharmaceuticals AB

Virdings Alle 32B

Entity Type: 99

Trademark Details

Filing Date

March 2, 2016

Registration Date

March 14, 2017

Published for Opposition

December 27, 2016

Cancellation Date

September 29, 2023

Goods & Services

Pharmaceutical preparations, namely, anti-cancer preparations and preparations for treatment of central nervous system diseases, immune system disorders, metabolic diseases, lung diseases, and bacterial and fungal infections; pharmaceutical preparations for tissue targeting for the treatment of cancer, immune system disorders, central nervous system diseases, metabolic diseases, lung diseases, and bacterial and fungal infections; pharmaceutical preparations for controlled release of anti-cancer drugs and drugs for the treatment of immune system disorders, central nervous system diseases, metabolic diseases, lung diseases, and bacterial and fungal infections; chemical preparations for pharmaceutical purposes, namely, for the treatment of cancer, immune system disorders, central nervous system diseases, metabolic diseases, lung diseases, and bacterial and fungal infections; chemical preparations for medical purposes, namely, for the treatment of cancer, immune system disorders, central nervous system diseases, metabolic diseases, lung diseases, and bacterial and fungal infections; chemical preparations for veterinary purposes, namely, for the treatment of cancer, immune system disorders, central nervous system diseases, metabolic diseases, lung diseases, and bacterial and fungal infections in mammals; veterinary preparations for the treatment of cancer, immune system disorders, central nervous system diseases, metabolic diseases, lung diseases, and bacterial and fungal infections in mammals

Filing History

TOTAL INVALIDATION PROCESSED BY THE IB
Jul 20, 2024 INNT
TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
Jun 27, 2024 INTS
INVALIDATION PROCESSED
Jun 27, 2024 INPC
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
Jun 14, 2024 INTR
CANCELLED SECTION 71
Sep 29, 2023 C71T
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Mar 14, 2022 REM3
NEW REPRESENTATIVE AT IB RECEIVED
Nov 23, 2018 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Jul 8, 2017 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Jun 21, 2017 FICS
FINAL DISPOSITION PROCESSED
Jun 21, 2017 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jun 14, 2017 FICR
REGISTERED-PRINCIPAL REGISTER
Mar 14, 2017 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 27, 2016 NPUB
PUBLISHED FOR OPPOSITION
Dec 27, 2016 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Dec 7, 2016 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 21, 2016 CNSA
REFUSAL PROCESSED BY IB
Nov 18, 2016 RFNT
NEW REPRESENTATIVE AT IB RECEIVED
Nov 10, 2016 NREP
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 1, 2016 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 1, 2016 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 1, 2016 TROA
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Oct 27, 2016 RFCS
REFUSAL PROCESSED BY MPU
Oct 27, 2016 RFRR
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Oct 15, 2016 TCCA
APPLICATION FILING RECEIPT MAILED
Oct 8, 2016 MAFR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Oct 7, 2016 RFCR
NON-FINAL ACTION WRITTEN
Oct 6, 2016 CNRT
ASSIGNED TO EXAMINER
Oct 4, 2016 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 4, 2016 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Oct 1, 2016 REPR